Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-09-25
DOI
10.1111/cas.14657
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
- (2020) Saad Z Usmani et al. Lancet Haematology
- Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
- (2019) Thomas Martin et al. Blood Cancer Journal
- Mechanism of action of a new anti-CD38 antibody: enhancing myeloma immunotherapy
- (2019) Fabio Malavasi et al. CLINICAL CANCER RESEARCH
- The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa
- (2019) Laura Moreno et al. CLINICAL CANCER RESEARCH
- A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
- (2019) Joseph Mikhael et al. BLOOD
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Amelioration of NK cell function driven by Vα24 + invariant NKT cell activation in multiple myeloma
- (2018) Tomonori Iyoda et al. CLINICAL IMMUNOLOGY
- CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
- (2018) Kristine A. Frerichs et al. Expert Review of Clinical Immunology
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- IMiDs through loss of Ikaros and Aiolos primes myeloma cells for daratumumab mediated killing by upregulation of CD38
- (2018) Pasquale L. Fedele et al. BLOOD
- Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
- (2018) Meletios A. Dimopoulos et al. HAEMATOLOGICA
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
- (2018) Niels W.C.J. van de Donk et al. Frontiers in Immunology
- CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
- (2018) Fabio Morandi et al. Frontiers in Immunology
- Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
- (2017) Shinsuke Iida et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Monoclonal antibody therapy in multiple myeloma
- (2017) C Touzeau et al. LEUKEMIA
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
- (2017) C S Chim et al. LEUKEMIA
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
- (2014) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now